The Regulation of Tumor Suppressor p63 by the Ubiquitin-Proteasome System

Stephen R. Armstrong 1, Hong Wu 1, Benfan Wang 1, Yasser Abuetabh 1, Consolato Sergi 2 and Roger P. Leng 1,*

1 370 Heritage Medical Research Center, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2S2, Canada; ar2@ualberta.ca (S.R.A.); hwu8@ualberta.ca (H.W.); benfan@ualberta.ca (B.W.); abuetabh@ualberta.ca (Y.A.)
2 Department of Laboratory Medicine and Pathology (5B4.09), University of Alberta, Edmonton, AB T6G 2B7, Canada; sergi@ualberta.ca
* Correspondence: rleng@ualberta.ca; Tel.: +1-780-492-4985; Fax: +1-780-492-9974

Academic Editor: Tomoo Iwakuma
Received: 1 October 2016; Accepted: 30 November 2016; Published: 6 December 2016

Abstract: The protein p63 has been identified as a homolog of the tumor suppressor protein p53 and is capable of inducing apoptosis, cell cycle arrest, or senescence. p63 has at least six isoforms, which can be divided into two major groups: the TAp63 variants that contain the N-terminal transactivation domain and the ∆Np63 variants that lack the N-terminal transactivation domain. The TAp63 variants are generally considered to be tumor suppressors involved in activating apoptosis and suppressing metastasis. ∆Np63 variants cannot induce apoptosis but can act as dominant negative inhibitors to block the function of TAp53, TAp73, and TAp63. p63 is rarely mutated in human tumors and is predominately regulated at the post-translational level by phosphorylation and ubiquitination. This review focuses primarily on regulation of p63 by the ubiquitin E3 ligase family of enzymes via ubiquitination and proteasome-mediated degradation, and introduces a new key regulator of the p63 protein.

Keywords: p63; Mdm2; Mdm4; AIP 4; WWP1; E3 ligases; ubiquitination; degradation

1. The p53 Family of Tumor Suppressors

The p53 family of transcription factors is centrally important in cancer research. This family contains the tumor suppressor protein that is most frequently inactivated in cancer, p53, and two other family members, p63 and p73. p53 was discovered in 1979 through SV40 viral transformation studies in animals [1–3], during the era when cancer was hypothesized to result from viral transformation. One SV40 antigen, a 53 kDa protein, was thought to be a viral oncogene but was later identified as a host protein [1]. In 1983, the protein was named p53 and was soon after classified not as an oncogene but as a tumor suppressor [1,2]. p53 is inactivated in approximately 80% of all human cancers and mutated in approximately 50% [3–7]. It acts as an important tumor suppressor in response to genotoxic damage [6]. Its tumor suppressor function is thought to increase the expression of transactivating cell cycle arrest proteins (p21) and apoptotic proteins (bax, PUMA) [5,6]. Mutant p53 in cancer loses the ability to transactivate these proteins [8]. p53 was thought to be the only tumor suppressor in its family until 1997, when two p53 homolog proteins were discovered, p63 and p73 [9–11]. p63 was cloned and characterized in 1998 [10,12,13]. Originally, p63 and p73 were assumed to function similarly to p53. However, both p63 and p73 have now been shown to also play developmental roles.
2. Structure and Properties of p53 Family Proteins

p53, p63, and p73 share three domains (Figure 1). An N-terminal acidic transactivation domain (TAD) is responsible for transactivation of target genes. A highly conserved DNA-binding domain (DBD) is responsible for binding to target DNA sequences; the DNA-binding domain has 65% identity between p63 and p53, 62% identity between p73 and p53, and 91% identity between p63 and p73 [14]. An oligomerization domain (OD) is responsible for protein oligomerization into active tetrameric forms [2,3,14,15]. The genes encoding p63 and p73 (TP63 and TP73, respectively) [2] have unique properties compared to the p53 gene (TP53). TP63 and TP73 contain both a primary promoter (P1) upstream of the coding sequence and an alternative promoter (P2) located in intron 3 [2,13,15]. Unlike TP63 and TP73, the P2 promoter of TP53 is located in intron 4 and is able to generate Δ133p53, which lacks the transactivation domain and part of the DNA-binding domain [2,16]. The P2 promoter regulates expression of Δ133p53 and Δ160p53. The Δ133p53 isoform stimulates tumor angiogenesis and progression [16].

![Figure 1. Six isoforms of p63 including all domains of each transcript including the transactivation domain (TAD), the proline-rich domain (PRD), the DNA-binding domain (DBD), the oligomerization domain (OD), the second transactivation domain (TA2), the sterile α motif domain (SAM), and the transactivation-inhibition domain (TID).](image)

The P1 and P2 promoters of TP63 and TP73 encode two strikingly different groups of isoforms: P1 encodes p53-like isoforms that contain the N-terminal acidic transactivation domain and are designated TAp63/TAp73, while P2 generates N-terminal truncated isoforms that lack this transactivation domain and are designated ΔNp63/ΔNp73 [13,15,17]. The N-terminal transactivation domain is thought to be important for p53-like tumor suppressor functions. Both the TAp63 and TAp73 isoforms are able to transactivate p53-responsive genes related to tumor suppression, such as p21 and bax [13,15]. Although the ΔNp63 and ΔNp73 variants lack the N-terminal transactivation domain [13,15], they are able to transactivate other targets through the function of a second transactivation transactivation domain [18,19].

Further, both p63 and p73 have isoforms that undergo alternative splicing at the C-termini of exons 10–14, producing at least three variants for p63 (Figure 1) and at least nine for p73 [2,9,13,15]. Between the alternative promoters and the splicing variants, p63 has at least six isoforms (TAp63α (full length), TAp63β, TAp63γ, ΔNp63α, ΔNp63β, ΔNp63γ) [2,5,13,15,20] and p73 has at least eighteen isoforms [15]. The α variants of both p63 and p73 contain a sterile α motif domain (SAM) (Figure 1), which is thought to be responsible for protein–protein interactions [2,3,6] and is involved in development [16]. A proline-rich domain (PRD) is present on all p63 isoforms (Figure 1) and is necessary for TAp63β’s transactivation activity and for its ability to mediate apoptosis [21]. α variants
of p63 also contain a second transactivation domain (TA2), encoded by exons 11 and 12, that occurs just before the sterile α motif domain [18]. All ΔNp63 variants contain a third transactivation domain at the N-terminus. These additional transactivation domains confer the ability of ΔNp63 variants to transactivate target genes, such as p21 and GADD45, two mediators of cell cycle arrest [19].

3. Expression and Functions of p53 Family Proteins

All three members of the p53 family, p53, p63, and p73, arise from a p63/p73 ancestor gene found in almost all invertebrates. This gene was duplicated during the evolution of early vertebrates to produce the p53 gene, which is primarily a tumor suppressor that controls the cell cycle and apoptosis. The p63/p73 ancestor gene was later duplicated again during the evolution of bony fish to produce the p63 and p73 genes, which shared function with p53 but also became specialized in developmental roles [22]. Unlike p53, which is expressed in all cells, p63 and p73 are specifically expressed in epithelial tissues of the ectoderm [23]. p63 is involved in epithelial development [24,25], cell metabolism [26,27], and senescence [27]; p73 is involved in neurogenesis, pheromone signaling, and cerebrospinal fluid dynamics [15,28,29].

Conflicting expression and functional data cast doubt on whether these two proteins (particularly p63) function as p53-like tumor suppressors or as oncogenes. p63 rarely undergoes loss of heterozygosity or mutation [6,30]. In fact, the chromosome on which the p63 gene is located (3q27–29 [13]) is frequently amplified in various cancers, including lung cancer and squamous cell carcinomas of the head and neck [31–33], suggesting an oncogenic role [15,34] (Figure 2). p73 is located on a chromosome region 1p36 [9] that is frequently amplified in various cancers, including breast and colorectal carcinomas [2]. ΔNp63 variants are often overexpressed in cancers of urinary bladder, esophagus, and lung [33–39]; TAp63 variants are underexpressed in osteosarcomas and carcinomas of the bladder, oral mucosa, and larynx [37,40–42], but overexpressed in malignant lymphomas [43].

Unlike mice lacking p53, which develop normally and generate spontaneous tumors [35], lack of both p63 alleles (p63−/−) is embryonically lethal, resulting in mice with severe developmental abnormalities including lack of epithelium and anomalies of limb development [24]. Mice lacking both p73 alleles (p73−/−) show neurological abnormalities but no evidence of tumorigenesis [28]. However, when mice lack one allele of either p63 or p73 (p63+/− or p73+/−), their developmental abnormalities are not severe and they do develop tumors [36]. Furthermore, mice with heterozygous deletions in p53 and either p63 or p73 develop tumors with a greater degree of metastasis than mice with only p53 heterozygous deletions [36].

ΔNp63 variants are able to inactivate the transactivation function of p53 and variants of both p63 and p73 by directly competing with promoter regions [13,15]. ΔNp63 variants can also inactivate transactivation function by incorporating into heterotetramers and acting in a dominant negative fashion [13,15]. TAp73 can transactivate p53 tumor suppressor targets such as p21 [9], but ΔNp73 is able to inhibit the tumor suppressor functions of p53 and TAp73 through dominant negative heterotetramers or promoter competition [17,28,29,44,45]. TAp73 and p53 both transactivate the expression of ΔNp73, creating a negative feedback loop [44]. Knockout studies of p53, p63, and p73 in mouse embryo fibroblasts have demonstrated that p53 requires either TAp63 or TAp73 to induce apoptosis. When both p63 and p73 are knocked out together, p53 is unable to induce expression of pro-apoptotic genes, including bax, Noxa, and PERP [46]. On the basis of these observations, TAp63, and TAp73 variants are often thought to function as tumor suppressors and the ΔNp63 and ΔNp73 variants as oncogenes [2,36,46]. The ratios between the TA and ΔN variants of these proteins may be important in determining overall oncogenic or tumor suppressive properties [15,43,47].

The DNA-binding domains of the p53, p63, and p73 transcription factors recognize specific response elements (REs) for binding. p53 recognizes p53 response elements (p53RE) upstream of genes belonging to bax, p21, Noxa, PLIMA, and many others [48]. p63 can bind to both p53REs and p73REs, but p63 is at least twice as active in transcription when binding to p63REs, which contain different base pairs at the 5th and 16th position compared to the p53RE [49,50]. The specific
p63RE sequence is 5′-RRRC(A/G)(A/T)GYYYYRRRC(A/T)(C/T)GYYY-3′ [49,50], with key differences from the p53RE highlighted in bold. Examples of genes that p63 preferentially transactivates to a higher degree than p53 are PTPN14 and ING1, tumor suppressors that are involved in promoting apoptosis, cell cycle arrest, and senescence [49]. Recent functional experiments have demonstrated that TAp63 specifically transactivates Dicer, Sharp-1, and Maspin, factors involved in suppressing metastasis [51–53]. This work strengthens the link between TAp63 isoforms and tumor suppressor function. Since TAp63 isoforms likely have tumor suppression roles, understanding how they and the oncogenic ∆Np63 isoforms are regulated is important.

4. Kinases and p63 Phosphorylation

p63 is thought to be regulated predominantly at the protein level [54]. Self-regulation of the TAp63α isoform is mediated through a unique transactivation inhibition domain (Figure 1) that can interact directly with the transactivation domain and form inactive dimers [15,55,56]. This transactivation inhibition domain can be cleaved off by caspases 3, 6, 7, and 8 during apoptosis.

Figure 2. Overview of the regulation of p63 isoforms. This figure outlines the different ubiquitin E3-ligases regulate p63 isoforms and how they interact with the p63 isoforms and subsequent proteasome degradation.
enhancing TAp63α’s transactivation ability [57]. ∆Np63 variants can inactivate TAp63 variants by either direct promoter competition, or by acting in a dominant negative fashion by forming heterotetramers with TAp63 [13]. Mutant p53 variants are frequently thought to function in a dominant negative function towards TAp63 [58,59] and TAp73 [60] in a similar fashion as ∆Np63. p63 is commonly regulated by post-translational modification, including phosphorylation by various kinases to activate p63 variants. Kinases that activate TAp63 variants include c-Abl [61], Cables1 [62], IKKβ [63], Pin1 [64], PML [65], and TLR3 [66]. Kinases, such as PIK1 [67], inhibit TAp63 variants by phosphorylation of Ser52 in the transactivation domain. Kinases that activate ∆Np63 variants include c-Abl [68], Pin1 [64], and PML [65], while kinases that inhibit ∆Np63 variants include ATM [69], CDK2 [69], HIPK2 [70], p38 [71], p70s6K [69], and Raf1 [72].

5. The Ubiquitin-Proteasome System and p63 Regulation

Ubiquitination is another common pathway for p63 regulation, usually via negative regulation of p63 isoforms through the ubiquitin-proteasome system. This system is a major pathway for regulating the cellular proteome by targeting specific proteins for proteasome-mediated degradation [73]. The proteasome is a large multi-subunit protein with a 20S core complex responsible for proteolysis and a 19S regulatory complex responsible for protein recognition [73]. To be recognized for degradation by the proteasome, substrates must first be tagged with ubiquitin, a small 8.5 kDa protein [73,74]. This post-translational modification is carried out by three classes of enzymes designated E-1, E-2, and E-3. E-1 activation enzymes activate ubiquitin in an ATP-dependent manner, attaching it to a cysteine residue of an E-2 conjugation enzyme. The E-2 conjugation enzyme acts in concert with an E-3 ligase enzyme in order to attach ubiquitin to a lysine residue of a target substrate [73,75].

E-3 ligases are substrate-specific [73] and number in the hundreds [76], but can be subdivided into different classes depending on their catalytic domains. RING (really interesting new gene)-type E-3 ligases act as a scaffold, binding to the E2 enzyme and target substrate and bringing them into close proximity. The RING domain catalyzes direct attachment of ubiquitin from the E-2 enzyme to the target substrate in this way [75,77]. U-box domains are structurally similar to RING domains, and function in the same way, but are stabilized by hydrogen bonding rather than zinc ion coordination [78,79]. HECT (homologous to E6-AP carboxyl terminus)-type E-3 ligases act differently, functioning as a catalytic intermediate in transfer of ubiquitin from the E-2 enzyme onto a cysteine residue of the HECT E-3 ligase and then directly to a lysine residue of the target substrate [73,75].

Target substrates can be mono-ubiquitinated (one ubiquitin molecule attached), multi-ubiquitinated (multiple ubiquitin molecules attached to different regions of the substrate) or poly-ubiquitinated (a ubiquitin chain of multiple ubiquitin molecules attached to the substrate [80]). Mono-ubiquitination is involved in endocytosis, membrane trafficking, and subcellular localization [80–82], while poly-ubiquitination is involved in protein degradation. Poly-ubiquitination links ubiquitin chains through the ubiquitin lysine residues K6, K11, K27, K29, K33, K48, and K63 [80]. The proteosome can recognize K48-linked poly-ubiquitin chains that are at least four ubiquitin proteins long [83], although K6-, K11-, K27-, and K29-linked chains have also been implicated in proteasome degradation [84]. Poly-ubiquitination requires participation of an E-4 enzyme responsible for facilitating ubiquitin chain elongation [73,75], although some E-3 ligases such as those that contain U-box domains also possess E-4 function [85,86].

Multiple E-3 ligases are responsible for regulating the p63 protein. Mdm2 (murine double minute-2), the most well-known, is an E-3 ligase containing the RING domain that can target p53 for degradation [87] in cooperation with an E-4 enzyme UBE4B [88]. Mdm2 can also mono-ubiquitinate p63 and p73 but is unable to cause degradation of either protein [89–92]. Its interaction with p63 and p73 is capable of interfering with their transactivation function, likely by exporting them from the nucleus into the cytoplasm [90]. However, the literature contains some disagreement: one study found Mdm2 unable to inhibit p63 function [91], another found that Mdm2 actually stabilized p63, increasing both its expression and its function [93], while yet another found no interaction between Mdm2 and
p63 [94]. Mdm2 is able to bind to p53, p63, and p73 through an FxxθxxL sequence (where θ is leucine or isoleucine and x is any amino acid) located in the transactivation domain [92]. Further, both p53 [95] and TAp73 [15] are able to transactivate Mdm2, providing a negative feedback loop for their own expression. Although Mdm2 is incapable of targeting p63 for degradation, it can cooperate with Fbw7 (an F-box ligase) to poly-ubiquitinate ΔNp63 and target it for proteasome degradation [89]. MdmX is an E-3 ligase related to Mdm2, but it does not have the ability to target any of the p53 family members for degradation and cannot interfere with p63 or p73 function [90,91].

Pirh2 (p53-induced protein with a RING-H2 domain) [96] is a RING-containing E-3 ligase able to bind to and target all members of the p53 family for degradation [97–100]. Pirh2 is able to induce degradation of both TAp63 and ΔNp63 isoforms [99], in cooperation with the E-2 enzyme UbcH5b [97]. Pirh2 can also induce degradation of p73 [99,101], and p21 [86]. It can be transactivated by p53, another example of a negative feedback loop and possible competition between family members [96].

Itch/AIP4 (atrophin-1 interacting protein 4) [102] is a HECT E-3 ligase that can target both p63 and p73 for proteasome degradation [103,104]. It is considered the major regulator of p63 protein, able to target all isoforms for proteasome degradation [102,104,105]. Itch/AIP4 functions as a monomer with four WW protein–protein interaction domains and a C-terminal HECT domain [102]. It requires its HECT domain for ubiquitination [104]. The WW domains recognize the PY motif (a short proline-rich segment PPPXY) in the proline-rich domain of p63 and p73, which is located between the transactivation and DNA-binding domains [102]. Phosphorylation of threonine on this motif is crucial for WW interaction and subsequent ubiquitination by Itch/AIP4 [106].

Nedd4 is a HECT-containing E-3 ligase able to bind to ΔNp63, ubiquitinate it, and target it for degradation [107]. It binds ΔNp63α, but not ΔNp63γ, recognizing a PY motif on ΔNp63α’s sterile α motif domain. Nedd4 contains three central WW domains, in addition to the C-terminal HECT domain, which are likely responsible for recognizing the PY motif on ΔNp63α [107]. Although TAp63α also contains the sterile α motif domain, the literature contains no mention of Nedd4 being able to target TAp63α for degradation, and Nedd4 may be specific to the oncogenic α isoforms of the p63 protein.

WWP1 is a HECT-containing E-3 ligase targeting both TAp63 and ΔNp63 for proteasome degradation. Similarly to Itch/AIP4, it binds to the PY motif on those proteins using its WW domains and ubiquitinates them using its HECT domain. WWP1 has both tumor suppression and oncogenic roles that are thought to depend on the context of the cell line in which it is expressed. Knockdown of WWP1 in the breast cancer 184B5 cell line is associated with a decrease of ΔNp63 levels, while knockdown of WWP1 in colorectal HCT116 cells increases TAp63 expression and sensitivity to genotoxic stress [108]. The regulation of p63 by several ubiquitin E3 ligases is summarized in Figure 2.

6. Summary

p63 is a highly complex set of proteins with isoform-dependent functions ranging from development to tumor suppression to tumor promotion. Both TAp63 and ΔNp63 are tightly regulated at the protein level. Multiple E-3 ligases control their protein levels, including RING-containing and HECT-containing E-3 ligases. Some E-3 ligases are isoform specific, while others can only target certain p63 splicing variants for degradation. Like p63 itself, these E-3 ligases are often seen as oncogenic or tumor-suppressive depending on which isoforms they target, and their roles may be context dependent.

Acknowledgments: This work was supported by grants from Women & Children’s Health Research Institute (WCHRI), the Alberta Heritage Foundation for Medical Research (AHFMR), Canadian Breast Cancer Foundation, and Canadian Institutes of Health Research (CIHR) to Roger P. Leng.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Soussi, T. The history of p53. A perfect example of the drawbacks of scientific paradigms. EMBO Rep. 2010, 11, 822–826. [CrossRef] [PubMed]
2. Yang, A.; McKeon, F. p63 and p73: P53 mimics, menaces and more. *Nat. Rev. Mol. Cell Biol.* 2000, 1, 199–207. [CrossRef] [PubMed]

3. De Laurenzi, V.; Melino, G. Evolution of functions within the p53/p63/p73 family. *Ann. N. Y. Acad. Sci.* 2000, 926, 90–100. [CrossRef] [PubMed]

4. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C.C. p53 mutations in human cancers. *Science* 1991, 253, 49–53. [CrossRef] [PubMed]

5. Khoury, M.P.; Bourdon, J.C. p53 isoforms: An intracellular microprocessor? *Genes Cancer* 2011, 2, 453–465. [CrossRef] [PubMed]

6. Kaghad, M.; Bonnet, H.; Creancier, L.; Biscan, J.C.; Valent, A.; Minty, A.; Chalon, P.; LeLias, J.M.; Kaghad, M. p53, a novel protein with strong homology to the tumor suppressor p53. *Nature* 1991, 351, 40–44. [CrossRef] [PubMed]

7. Vousden, K.H.; Lu, X. Live or let die: The cell's response to p53. *Cell* 1999, 98, 255–266. [CrossRef] [PubMed]

8. Oren, M.; Rotter, V. Mutant p53 gain-of-function in cancer. *Cold Spring Harb. Perspect. Biol.* 2010, 2, a001107. [CrossRef] [PubMed]

9. Kaghad, M.; Bonnet, H.; Yang, A.; Creancier, L.; Biscan, J.C.; Valenti, A.; Minty, A.; Chalon, P.; LeLias, J.M.; Dumont, X.; et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. *Cell* 1997, 90, 809–819. [CrossRef]

10. Trink, B.; Okami, K.; Wu, L.; Suriyanpong, V.; Jen, J.; Sidransky, D. A new human p53 homologue. *Nat. Med.* 1998, 4, 747–748. [CrossRef] [PubMed]

11. Schmale, H.; Bamberger, C. A novel protein with strong homology to the tumor suppressor p53. *Oncogene* 1997, 15, 1363–1367. [CrossRef] [PubMed]

12. Osada, M.; Ohba, M.; Kawahara, C.; Ishioka, C.; Kanamaru, R.; Katoh, I.; Ikawa, Y.; Nimura, Y.; Nakagawara, A.; Obinata, M.; et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. *Nat. Med.* 1998, 4, 839–843. [CrossRef] [PubMed]

13. Yang, A.; Kaghad, M.; Wang, Y.; Gillett, E.; Fleming, M.D.; Dotsch, V.; Andrews, N.C.; Caput, D.; McKeon, F. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. *Mol. Cell Biol.* 1999, 19, 90–95. [CrossRef] [PubMed]

14. Yang, A.; Kaghad, M.; Caput, D.; McKeon, F. On the shoulders of giants: p63, p73 and the rise of p53. *Trends Genet.* 2002, 18, 90–95. [CrossRef]

15. Moll, U.M.; Slade, N. p63 and p73: Roles in development and tumor formation. *Mol. Cancer Res.* 2004, 2, 371–386. [PubMed]

16. Bernard, H.; Garmy-Susini, B.; Ainaou, N.; van den Berghe, L.; Peurichard, A.; Javerzat, S.; Bikfalvi, A.; Lane, D.P.; Bourdon, J.C.; Prats, A.C. The p53 isoform, p133p63, stimulates angiogenesis and tumor progression. *Oncogene* 2013, 32, 2150–2160. [CrossRef] [PubMed]

17. Ishimoto, O.; Kawahara, C.; Enjo, K.; Obinata, M.; Nukiwa, T.; Ikawa, S. Possible oncogenic potential of Np73: A newly identified isoform of human p73. *Cancer Res.* 2002, 62, 636–641. [PubMed]

18. Ghione, P.; Bolognese, F.; Duijff, P.H.; van Bokhoven, H.; Mantovani, R.; Guerrini, L. Complex transcriptional effects of p63 isoforms: Identification of novel activation and repression domains. *Mol. Cell. Biol.* 2002, 22, 8659–8668. [CrossRef] [PubMed]

19. Dohn, M.; Zhang, S.; Chen, X. p63α and Np63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. *Oncogene* 2001, 20, 3193–3205. [CrossRef] [PubMed]

20. Petitjean, A.; Ruptier, C.; Tribollet, V.; Hautefeuille, A.; Chardon, F.; Cavard, C.; Puisieux, A.; Hainaut, P.; de Fromentel, C.C. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross-talk with p53. *Carcinogenesis* 2008, 29, 273–281. [CrossRef] [PubMed]

21. Helton, E.S.; Zhang, J.; Chen, X. The proline-rich domain in p63 is necessary for the transcriptional and apoptosis-inducing activities of Tap63. *Oncogene* 2008, 27, 2843–2850. [CrossRef] [PubMed]

22. Belyi, V.A.; Ak, P.; Markert, E.; Wang, H.; Hu, W.; Puzio-Kuter, A.; Levine, A.J. The origins and evolution of the p53 family of genes. *Cold Spring Harb. Perspect. Biol.* 2010, 2, a001198. [CrossRef] [PubMed]

23. Westfall, M.D.; Pietenpol, J.A. p63: Molecular complexity in development and cancer. *Carcinogenesis* 2004, 25, 857–864. [CrossRef] [PubMed]

24. Yang, A.; Schweitzer, R.; Sun, D.; Kaghad, M.; Walker, N.; Bronson, R.T.; Tabin, C.; Sharpe, A.; Caput, D.; Crum, C.; et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature* 1999, 398, 714–718. [PubMed]
25. Mills, A.A.; Zheng, B.; Wang, X.J.; Vogel, H.; Roop, D.R.; Bradley, A. p63 is a p53 homologue required for limb and epidermal morphogenesis. *Nature* **1999**, *398*, 708–713. [PubMed]
26. Guo, X.; Keyes, W.M.; Papazoglou, C.; Zuber, J.; Li, W.; Lower, S.W.; Vogel, H.; Mills, A.A. TAp63 induces senescence and suppresses tumorigenesis in vivo. *Nat. Cell Biol.* **2009**, *11*, 1451–1457. [CrossRef] [PubMed]
27. Su, X.; Gi, Y.J.; Chakravarty, D.; Chan, I.L.; Zhang, A.; Xia, X.; Tsai, K.Y.; Flores, E.R. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. *Cell Metab.* **2012**, *16*, 511–525. [CrossRef] [PubMed]
28. Yang, A.; Walker, N.; Bronson, R.; Kaghad, M.; Oosterwegel, M.; Bonnin, J.; Vagner, C.; Bonnet, H.; Dikkes, P.; Sharpe, A.; et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. *Nature* **2000**, *404*, 99–103. [CrossRef] [PubMed]
29. Pozniak, C.D.; Barnabe-Heider, F.; Rymar, W.; Lee, A.F.; Sadikot, A.F.; Miller, F.D. p73 is required for survival and maintenance of CNS neurons. *J. Neurosci.* **2002**, *22*, 9800–9809. [PubMed]
30. Irwin, M.S.; Kaelin, W.G. Role of the newer p53 family proteins in malignancy. *Apoptosis* **2001**, *6*, 17–29. [CrossRef] [PubMed]
31. Hibi, K.; Trink, B.; Patturajan, M.; Westra, W.H.; Caballero, O.L.; Hill, D.E.; Ratovitski, E.A.; Jen, J.; Sidransky, D. AIS is an oncogene amplified in squamous cell carcinoma. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 5462–5467. [CrossRef] [PubMed]
32. Yamaguchi, K.; Wu, I.; Caballero, O.L.; Hibi, K.; Trink, B.; Resto, V.; Cairns, P.; Okami, K.; Kock, W.M.; Sidransky, D.; et al. Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. *Int. J. Cancer* **2000**, *86*, 684–689. [CrossRef]
33. Massion, P.P.; Taflan, P.M.; Rahman, S.J.; Yildiz, P.; Shry, Y.; Edgerton, M.E.; Westfall, M.D.; Roberts, J.R.; Pieterpol, J.A.; Carbone, D.P.; et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. *Cancer Res.* **2003**, *63*, 7113–7121. [PubMed]
34. Rocco, J.W.; Leong, C.O.; Kupferwasser, N.; DeYoung, M.P.; Ellis, L.W. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. *Cancer Cell* **2006**, *9*, 45–56. [CrossRef] [PubMed]
35. Donehower, L.A.; Harvey, M.; Slagle, B.L.; McArthur, M.J.; Montgomery, C.A.; Brutel, J.S.; Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature* **1992**, *356*, 215–221. [CrossRef] [PubMed]
36. Flores, E.R.; Sengupta, S.; Miller, J.B.; Newman, J.J.; Bronson, R.; Crowley, D.; Yang, A.; McKeon, F.; Jacks, T. Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. *Cancer Cell* **2005**, *7*, 363–373. [CrossRef] [PubMed]
37. Park, B.J.; Lee, S.J.; Kim, J.I.; Lee, S.J.; Lee, C.H.; Chang, S.G.; Park, J.H.; Chi, S.G. Frequent alteration of p63 expression in human primary bladder carcinomas. *Cancer Res.* **2000**, *60*, 3370–3374. [PubMed]
38. Hibi, K.; Nakayama, H.; Taguchi, M.; Kasai, Y.; Ito, K.; Akiyama, S.; Nakao, A. AIS overexpression in advanced esophageal cancer. *Clin. Cancer Res.* **2001**, *7*, 469–472. [PubMed]
39. Pelosi, G.; Pasini, F.; Olsen, S.C.; Pastorino, U.; Maisonneuve, P.; Sonzogni, A.; Maffini, F.; Pruneri, G.; Fraggetta, F.; Cavallo, A.; et al. p63 immunoreactivity in lung cancer: Yet another player in the development and lack of prognostic implications of p63 immunoreactivity. *Lab. Investig.* **2002**, *82*, 1327–1334. [CrossRef] [PubMed]
40. Chen, Y.K.; Hsue, S.S.; Lin, L.M. Expression of p63 (TA and ΔN isoforms) in human primary well differentiated buccal carcinomas. *Int. J. Oral Maxillofac. Surg.* **2004**, *33*, 493–497. [PubMed] [PubMed]
41. Pruneri, G.; Pignataro, L.; Manzotti, M.; Carboni, N.; Ronchetti, D.; Neri, A.; Cesana, B.M.; Viale, G. p63 in laryngeal squamous cell carcinoma: Evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. *Lab. Investig.* **2002**, *82*, 1327–1334. [CrossRef] [PubMed]
42. Park, H.R.; Kin, Y.W.; Park, J.H.; Maeng, Y.H.; Nojima, T.; Hashimoto, H.; Park, Y.K. Low expression of p63 and p73 in osteosarcoma. *Tumori* **2004**, *90*, 239–243. [PubMed]
43. Nylander, K.; Vojtesek, B.; Nenutil, R.; Lindgren, B.; Roos, G.; Zhanxiang, W.; Sjostrom, B.; Dahlqvist, A.; Coates, P.J. Differential expression of p63 isoforms and normal tissues and neoplastic cells. *J. Pathol.* **2002**, *198*, 417–427. [CrossRef] [PubMed]
44. Nakagawa, T.; Takahashi, M.; Ozaki, T.; Watanabe, K.K.; Todo, S.; Mizuguchi, H.; Nakagawara, A. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. *Mol. Cell. Biol.* **2002**, *22*, 2575–2585. [CrossRef] [PubMed]
45. Stiewe, T.; Theseling, C.C.; Putzer, B.M. Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA binding: Implications for tumorigenesis. *J. Biol. Chem.* 2002, 277, 14177–14185. [CrossRef] [PubMed]

46. Flores, E.R.; Tsal, K.Y.; Crowley, D.; Sengupta, S.; Yang, A.; McKeon, F.; Jacks, T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. *Nature* 2002, 416, 560–564. [CrossRef] [PubMed]

47. Deyoung, M.P.; Ellisen, L.W. p63 and p73 in human cancer: Defining the network. *Oncogene* 2007, 26, 5169–5183. [CrossRef] [PubMed]

48. Beckerman, R.; Prives, C. Transcriptional regulation by p53. *Cold Spring Harb. Perspect. Biol.* 2010, 2, a009353. [CrossRef] [PubMed]

49. Perez, C.A.; Ott, J.; Mays, D.J.; Pietenpol, J.A. p63 consensus DNA-binding site: Identification, analysis and application into a p63MH algorithm. *Oncogene* 2007, 26, 7363–7370. [CrossRef] [PubMed]

50. Ortt, K.; Sinha, S. Derivation of the consensus DNA-binding sequence for p63 reveals unique requirements that are distinct from p53. *FEBS Lett.* 2006, 580, 4544–4550. [CrossRef] [PubMed]

51. Tan, E.H.; Morton, J.P.; Timpson, P.; Tucci, P.; Melino, G.; Flores, E.R.; Sansom, O.J.; Vousden, K.H.; Muller, P.A. Functions of TAp63 and p53 in restraining the development of metastatic cancer. *Oncogene* 2014, 33, 3325–3333. [CrossRef] [PubMed]

52. Su, X.; Chakravarti, D.; Cho, M.S.; Liu, L.; Gi, Y.J.; Lin, Y.L.; Leung, M.L.; El-Naggar, A.; Creighton, C.J.; Suraokar, M.B.; et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. *Nature* 2010, 467, 986–990. [CrossRef] [PubMed]

53. Zou, Z.; Anisowicz, A.; Hendrix, M.J.; Thor, A.; Neveu, M.; Sheng, S.; Rafidi, K.; Seftor, E.; Sager, R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. *Science* 1994, 263, 526–529. [CrossRef] [PubMed]

54. Rossi, M.; Ageilan, R.I.; Neale, M.; Candi, E.; Salomeni, P.; Knight, R.A.; Croce, C.M.; Melino, G. The E3 ubiquitin ligase Itch controls the protein stability of p63. *Proc. Natl. Acad. Sci. USA* 2006, 103, 12753–12758. [CrossRef] [PubMed]

55. Zou, Z.; Anisowicz, A.; Hendrix, M.J.; Thor, A.; Neveu, M.; Sheng, S.; Rafidi, K.; Seftor, E.; Sager, R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. *Science* 1994, 263, 526–529. [CrossRef] [PubMed]

56. Deutsch, G.B.; Zielonka, E.M.; Coutandin, D.; Weber, T.A.; Schafer, B.; Hannewald, J.; Luh, L.M.; Durst, F.G.; Ibrahim, M.; Hoffmann, J.; et al. DNA damage in oocytes induces a switch of the quality control factor TAp63x from dimer to tetramer. *Cell* 2011, 144, 566–576. [CrossRef] [PubMed]

57. Sayan, B.S.; Sayan, A.E.; Yang, A.L.; Ageilan, R.I.; Candi, E.; Cohen, G.M.; Knight, R.A.; Croce, C.M.; Melino, G. Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. *Proc. Natl. Acad. Sci. USA* 2007, 104, 10871–10876. [CrossRef] [PubMed]

58. Stindt, M.H.; Muller, P.A.; Ludwig, R.L.; Kehrloesser, S.; Dotsch, V.; Vousden, K.H. Functional interplay between MDM2, p63/p73 and mutant p53. *Oncogene* 2015, 34, 4300–4310. [CrossRef] [PubMed]

59. Adorno, M.; Cordononsi, M.; Montagner, M.; Dupont, S.; Wong, C.; Henn, B.; Solari, A.; Bobishe, S.; Rondina, M.B.; Guzzardo, V.; et al. A Mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. *Cell* 2009, 137, 87–98. [CrossRef] [PubMed]

60. Di Como, C.J.; Gaiddon, C.; Prives, C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. *Mol. Cell. Biol.* 1999, 19, 1438–1449. [CrossRef] [PubMed]

61. Gonfloni, S.; di Tella, L.; Calderola, S.; Cannata, S.M.; Klinger, F.G.; de Bartolomeo, C.; Mattei, M.; Candi, E.; de Felici, M.; Melino, G.; et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. *Nat. Med.* 2009, 15, 1179–1185. [CrossRef] [PubMed]

62. Wang, N.; Guo, L.; Rueda, B.R.; Tilly, J.L. Cables1 protects p63 from proteasomal degradation to ensure deletion of cells after genotoxic stress. *EMBO Rep.* 2010, 11, 633–639. [CrossRef] [PubMed]

63. MacPartlin, M.; Zeng, S.X.; Lu, H. Phosphorylation and stabilization of TAp63gamma by IkB kinase-β. *J. Biol. Chem.* 2008, 283, 15754–15761. [CrossRef] [PubMed]

64. Li, C.; Chang, D.L.; Yang, Z.; Qi, J.; Liu, R.; He, H.; Li, D.; Xiao, Z.X. Pin1 modulates p63α protein stability in regulation of cell survival, proliferation and tumor formation. *Cell Death Dis.* 2013, 4, e943. [CrossRef] [PubMed]

65. Bernassola, F.; Oberst, A.; Melino, G.; Pandolfi, P.P. The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. *Oncogene* 2005, 24, 6982–6986. [CrossRef] [PubMed]
66. Sun, R.; Zhang, Y.; Lv, Q.; Liu, B.; Jin, M.; Zhang, W.; He, Q.; Deng, M.; Liu, X.; Li, G.; et al. Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform α (TAp63α). *J. Biol. Chem.* 2011, 286, 15918–15928. [CrossRef] [PubMed]

67. Komatsu, S.; Takenobu, H.; Ozaki, T.; Ando, K.; Koida, N.; Suenaga, Y.; Ichikawa, T.; Hishiki, T.; Chiba, T.; Iwama, A.; et al. Plik1 regulates liver tumor cell death by phosphorylation of TAp63. *Oncogene* 2009, 28, 3631–3641. [CrossRef] [PubMed]

68. Yuan, M.; Luong, P.; Hudson, C.; Gumdunsdottir, K.; Basu, S. c-Abl phosphorylation of ΔNp63α is critical for cell viability. *Cell Death Dis.* 2010, 1, e16. [CrossRef] [PubMed]

69. Huang, Y.; Sen, T.; Nagpal, J.; Upadhyay, S.; Trink, B.; Ratsvitsky, E.; Sidransky, D. ATM kinase is a master switch for the ΔNp63α phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. *Cell Cycle* 2008, 7, 2846–2855. [CrossRef] [PubMed]

70. Patterson, C. A new gun in town: The U box is a ubiquitin ligase domain. *Curr. Biol.* 2000, 10, R132–R134. [CrossRef] [PubMed]

71. Hildesheim, J.; Belova, G.I.; Tyner, S.D.; Zhou, X.; Vardanian, L.; Fornance, A.J. Gadd45α regulates matrix metalloproteinases by suppressing ΔNp63α and β-catenin via p38 MAP kinase and APC complex activation. *Oncogene* 2004, 23, 1829–1837. [CrossRef] [PubMed]

72. Di Costanzo, A.; Festa, L.; Duverger, O.; Vivo, M.; Gentileschi, M.; Bartolazzi, A.; Costanzo, A.; Sacchi, A.; Guerrini, L.; et al. HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage. *Oncogene* 2011, 30, 4802–4813. [CrossRef] [PubMed]

73. Jung, T.; Catalgol, B.; Grune, T. The proteasomal system. *Mol. Asp. Med.* 2009, 30, 191–296. [CrossRef] [PubMed]

74. Glickman, M.H.; Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. *Physiol. Rev.* 2002, 82, 373–428. [CrossRef] [PubMed]

75. Hochstrasser, M. Lingering mysteries of ubiquitin-chain assembly. *Drug Discov. Today* 2002, 7, 746–754. [CrossRef] [PubMed]

76. Mukhopadhyay, D.; Riezman, H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. *Science* 2007, 315, 201–205. [CrossRef] [PubMed]

77. Thrower, J.S.; Hoffmann, L.; Rechsteiner, M.; Pickart, C.M. Recognition of the polyubiquitin proteolytic signal. *EMBO J.* 2000, 19, 94–102. [CrossRef] [PubMed]

78. Xu, P.; Duong, D.M.; Seyfried, N.T.; Cheng, D.; Xie, Y.; Robert, J.; Rush, J.; Hochstrasser, M.; Finley, D.; Peng, J. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. *Cell* 2009, 137, 133–145. [CrossRef] [PubMed]

79. Ohi, M.D.; Vander Kooi, C.W.; Rosenberg, J.A.; Chazin, W.J.; Gould, K.L. Structural insights into the U-box, a domain associated with multi-ubiquitination. *Nat. Struct. Biol.* 2003, 10, 250–255. [CrossRef] [PubMed]

80. Imai, Y.; Soda, M.; Hatakeyama, S.; Akagi, T.; Hashikawa, T.; Nakayama, K.I.; Takahashi, R. CHIP is associated with Parkin, a gene responsible for familial Parkinson’s disease, and enhances its ubiquitin ligase activity. *Mol. Cell* 2002, 10, 55–67. [CrossRef]

81. Fang, S.; Jensen, J.P.; Ludwig, R.L.; Vousden, K.H.; Weissman, A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. *J. Biol. Chem.* 2000, 275, 8945–8951. [CrossRef] [PubMed]
88. Wu, H.; Pomeroy, S.L.; Ferreira, M.; Teider, N.; Mariani, J.; Nakayama, K.I.; Hatakeyama, S.; Tron, V.A.; Saltibus, L.F.; Spyropoulos, L.; et al. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. *Nat. Med.* 2011, 17, 347–356. [CrossRef] [PubMed]

89. Galì, E.; Rossi, M.; D’Alessandra, Y.; de Simone, M.; Lopardo, T.; Haupt, Y.; Alsheich-Bartok, O.; Anzi, S.; Shaulian, E.; Calabro, V.; et al. MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation. *J. Cell. Sci.* 2010, 123, 2423–2433. [CrossRef] [PubMed]

90. Kadakia, M.; Slader, C.; Berberich, S.J. Regulation of p63 function by Mdm2 and MdmX. *DNA Cell Biol.* 2001, 20, 321–330. [CrossRef] [PubMed]

91. Little, N.A.; Jochemsen, A.G. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. *Oncogene* 2001, 20, 4576–4580. [CrossRef] [PubMed]

92. Shin, J.S.; Ha, J.H.; Lee, D.H.; Ryu, K.S.; Bae, K.H.; Park, B.C.; Park, S.G.; Yi, G.S.; Chi, S.W. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition. *Cell Cycle* 2015, 14, 533–543. [CrossRef] [PubMed]

93. Calabro, V.; Mansueto, G.; Parisi, T.; Vivo, M.; Calogero, R.A.; La Mantia, G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. *J. Biol. Chem.* 2002, 277, 2674–2681. [CrossRef] [PubMed]

94. Wang, X.; Arooz, T.; Siu, W.Y.; Chiu, C.H.; Lau, A.; Yamashita, K.; Poon, R.Y. MDM2 and MDMX can interact with and promotes p53 protein degradation. *Oncogene* 2013, 12, 21479–21492. [CrossRef] [PubMed]

95. Barak, Y.; Juven, T.; Haffner, R.; Oren, M. Mdm2 expression is induced by wild type p53 activity. *EMBO J.* 1993, 12, 461–468. [PubMed]

96. Halaby, M.J.; Hakem, R.; Hakem, A. Pirh2: An E3 ligase with central roles in the regulation of cell cycle, DNA damage response, and differentiation. *Cell Cycle* 2013, 12, 2733–2737. [CrossRef] [PubMed]

97. Leng, R.P.; Lin, Y.; Ma, W.; Wu, H.; Lemmers, B.; Chung, S.; Parant, J.M.; Lozano, G.; Hakem, R.; Bechimol, S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. *Cell* 2003, 112, 779–791. [CrossRef]

98. Wu, H.; Leng, R.P. MDM2 mediates p73 ubiquitination: A new molecular mechanism for suppression of p73 function. *Oncotarget* 2015, 6, 21479–21492. [CrossRef] [PubMed]

99. Jung, Y.S.; Qian, Y.; Chen, X. The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation. *J. Biol. Chem.* 2011, 286, 35388–35395. [CrossRef] [PubMed]

100. Conforti, F.; Yang, A.L.; Piro, M.C.; Terrinoni, A.; Candi, E.; Tucci, P.; Thomas, G.J.; Knight, R.A.; Melino, G.; et al. PIR2/Rnf144B regulates epithelial homeostasis by mediating degradation of p21WAF1 and p63. *Oncogene* 2013, 32, 4758–4765. [CrossRef] [PubMed]

101. Wu, H.; Zeinab, R.A.; Flores, E.R.; Leng, R.P. Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination. *Mol. Cancer Res.* 2011, 9, 1780–1790. [CrossRef] [PubMed]

102. Melino, G.; Gallagher, E.; Ageilan, R.I.; Ageilan, R.I.; Knight, R.; Peschiarioli, A.; Rossi, M.; Scialpi, F.; Malatesta, M.; Zoocchi, L.; et al. Itch: A HECT-type E3 ligase regulating immunity, skin and cancer. *Cell Death Differ.* 2008, 15, 1103–1112. [CrossRef] [PubMed]

103. Rossi, M.; de Laurenzi, V.; Munarriz, E.; Green, D.R.; Liu, Y.C.; Vossden, K.H.; Cesareni, G.; Melino, G. The ubiquitin-protein ligase Itch regulates p73 stability. *EMBO J.* 2005, 24, 836–848. [CrossRef] [PubMed]

104. Rossi, M.; de Simone, M.; Pollice, A.; Santoro, R.; La Manita, G.; Guerrini, L.; Cababro, V. Itch/Alp4 associates with and promotes p63 protein degradation. *Cell Cycle* 2006, 5, 1816–1822. [CrossRef] [PubMed]

105. Melino, G.; Knight, R.A.; Cesareni, G. Degradation of p63 by Itch. *Cell Cycle* 2006, 5, 1735–1739. [PubMed]

106. Melino, G.; Knight, R.A.; Cesareni, G. Degradation of p63 by Itch. *Cell Cycle* 2006, 5, 1735–1739. [PubMed]

107. Bakkers, J.; Camacho-Carvajal, M.; Nowak, M.; Kramer, C.; Danger, B.; Hammerschmidt, M. Destabilization of ΔNp63α by Nedd4-mediated ubiquitination and Ube9-mediated sumoylation, and its implications on dorsoventral patterning of the zebrafish embryo. *Cell Cycle* 2005, 4, 790–800. [CrossRef] [PubMed]

108. Li, Y.; Zhou, Z.; Chen, C. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. *Cell Death Differ.* 2008, 15, 1941–1951. [CrossRef] [PubMed]